A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
Trial details
- Registry ID
- NCT04681066
- Drugs studied
- CM-4620 Injectable Emulsion or CM-4620-IE
TrialRedline tracks 5 clinical trials sponsored by CalciMedica, Inc.: 5 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRSNCT04681066 | CM-4620 Injectable Emulsion or CM-4620-IE | Completed | 2024-05-15Actual |
| A Study of Auxora in Patients With Severe COVID-19 PneumoniaNCT04345614 | Auxora (Part 1), Auxora (Part 2), Standard of Care (Part 1) | Completed | 2021-06-28Actual |
| CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRSNCT03401190 | CM4620 Injectable Emulsion (High Dose), CM4620 Injectable Emulsion (Low Dose) | Completed | 2019-02-14Actual |
| A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"NCT06374797 | Auxora | Terminated | 2026-04-06Actual |
| A Study of Auxora in Patients With Critical COVID-19 PneumoniaNCT04661540 | CM4620-IE (Injectable Emulsion) | Terminated | 2021-12-21Actual |
Names as written in the registry records.
NCT06374797 · CalciMedica, Inc.
Before: Estimated. After: Actual.
Before: 150 participants (planned). After: 122 participants (actual).
Before: Estimated. After: Actual.
Before: Jul 2026. After: 6 Apr 2026.
Before: Active not recruiting. After: Terminated.
NCT06374797 · CalciMedica, Inc.
Before: Apr 2026. After: Jul 2026.
NCT06374797 · CalciMedica, Inc.
Before: Mar 2026. After: Apr 2026.
Before: Recruiting. After: Active not recruiting.